H. Perez

Cleveland BioLabs, Inc. operates as a biopharmaceutical company, which engages in the research and development of drugs. It focuses on oncology and acute radiation syndrome. It offers Entolimod, Mobilan, CBL0137, and SA-702. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Buffalo, NY.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. Its products in pipeline include NS5A, PPI-668 and PPI-383 for treating hepatitis C virus infections. The company was founded by Omar K. Haffar, Antoun Nabhan and David V. Jobes in March 2006 and is headquartered in San Francisco, CA.

Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA.

Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA.

Accelerated Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in development of pre-existing pharmaceutical products for the treatment of various cancer indications. It offers a platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications under the Picoplatin brand. The company was founded by Michael Fonstein, Ekaterina E. Nikolaevskaya and Dmitry Prudnikov in May 2014 and is headquartered in Westport, CT.

Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands.